Good information Cave, thanks for posting it. If Crede has not even exercised their warrants yet, what is your theory on why our pps is so weak at present? Did that analyst article do this much damage and is continuing to hold us down? Are the shorts getting more aggressive? Is Crede a short now? Will FDA approval in June do anything for the pps? Will European approval do anything? This stock has been transformed from a strong 2.80-3.10 stock in early 2013 to a stock that no one now wants for 1.65!

And management gets huge salaries and guaranteed bonuses regardless of Lymphoseek sales and stock price performance. I have seen bonuses tied to share price again and again in the pharmaceutical industry, but not with this joke of a board and management team. Seems like the shareholder lawsuits are going to happen in the near future.

First, The company said they expected EU approval by the end of 2013 and it did not happen. Next, they said they expected it by the end of Q1. Wrong again! They appear to be expecting great results yet they are apparently doing sloppy and late submissions of their own documentation to the FDA and EU.

Final thought, the company has said that Lymphoseek sales for the year should be between $5 and $6 million for the year. Based on their bungled predictions so far, I sure hope this guidance was accurate. I don't think the share price can handle more Pykett and Larson disappointment.

Any best case scenario includes Ray Leonard's departure immediately and the prompt hiring of an experienced professional to replace him that will do the following:

1)Keep shareholders informed
2)Build shareholder value
3)Finding some oil wouldn't hurt either.

Ray Leonard has made millions of dollars as the CEO of Hyperdynamics and he has cost shareholders HUNDREDS OF MILLIONS OF DOLLARS!
His gravy train needs to end YESTERDAY!

Randy, what are you thinking will happen here?

Ray Leonard has dropped the ball so many times, he is luckier than a cat with 1000 lives. The rest of us are not.

Is all of this new mess the reason that the shareholder meeting was held in December? We have been misled again and again...

Tullow should have known about the DOJ investigation long before they signed on the dotted line to become the lead operator of the concession. If the DOJ investigation gets cleared up in HDY's favor, I'd like to see a billion dollar lawsuit filed against Tullow on behalf of Hyperdynamics and its shareholders. This nonsense of pulling the plug on drilling 30 days before drilling warrants answers IMMEDIATELY from Ray Leonard. I do not believe this is the end, and I think it is possible that Tullow may be buying the shares of Hyperdynamics under 2.00 with some plan to take over the company. The lack of solid information is causing longs to abandon the stock. No matter what, if HDY survives, a new CEO is in order. That change alone should put the pops back on track...

Oodles of questions here and damn few answers for now.

Unacceptable!

The real question now is, assuming that Navidea gets expanded approval for Lymphoseek in Europe AND fast-track approval from the FDA for explanded label use of Lymphoseek, when will sales from these two approvals generate sufficient revenue to eliminate fear of further dilution and increase shareholder value back to where it was (or even subsnatially higher than it was) prior to the Crede deal?

Still waiting...

It's about time this stock got back into the high .20s and .30s. Dr. Chan ignored shareholder value for long enough.

Management has dug a bottomless hole with this deceptive dilution that they said only a short time ago was not necessary. To make matters worse, they don't give a damn.

Tomorrow they might deliver good news. Even so, like so many of the company press releases that we have seen, although good, the stock closes DOWN FOR THE DAY.

With the ridiculous downward trend that the company set in motion over a month ago, a close at or above 2.00 tomorrow will be a miracle, unless of course they announce a buyout for $4 per share as they admit that they have no idea what they are doing and are all too happy to sell the company in an effort to maximize shareholder value.

And of course, if the news is taken badly tomorrow (or a buyout is not announced LOL) the stock could be pounded to 1.50 or lower.

Thanks Pykett and Larson!

"...granted 3.83 is a long way off in only 4.5 months."

YA THINK?

Where is casperboo when we need some wisdom?

Actually, clit whacker is more flattering than clit frigger.

Actually, clit whacker is more flattering than clit frigger.

The stock is underperforming! Call me anything you want - trader, short, buyer, seller, or even clit frigger.
Only the shorts can be happy with the pps at 1.93.

The stock is underperforming! Call me anything you want - trader, short, buyer, seller, or even clit frigger.
Only the shorts can be happy with the pps at 1.93.

Cabos, your post was empty, but it gives me an idea.

Are you implying that the company has nothing to say tomorrow?

The stock is trading as if bankruptcy is looming and there is no pipeline. The sky is falling because of the selling. Is it going to fall further because of company ineptitude? Maybe another offering will be announced tomorrow. Here's an idea Pykett - sell 50 million new shares for shares at 1.71 at a .22 cent discount from today's bid. Never mind the destructive effect on the pps, you could raise $85 million! Instead, maybe the company should buy back some shares on the open market at the incredible discount we are now seeing from the "2.84 unit price" that Crede paid. I suggest all share holders call Pykett's office NOW and demand that the company do such!

An investigation is warranted here. Did Bupp work with the shorts (or one big short) years ago and share some secret vulnerability that the company has?

The Crede financing alone should probably not be doing this much damage. Something is very wrong here.

Is European Approval not happening in 2013?

Is RIGS going to happen at all?

WTF is going on here?

The stock is trading as if bad news has leaked out and tomorrow we are going to hear that there have been no Lymphoseek sales in the past quarter and that an FDA denial of RIGScan has happened before the Phase III trial even starts.

1.92 X 1.93

EXPLAIN yourselves Pykett and Larson.

There is a massive stranglehold on the share price. I fully expect to see a law firm (or several law firms) step up and announce some sort of investigation and/or litigation against the company for this severe unwarranted deterioration in share price. This litigation of course, will not help with the cash burn that the company seems to be unable to help.

It is going to be a VERY U N P L E A S A N T conference call. The company knew this pps decline was coming. They also know damn well that angry hard questions are coming Wednesday.

Stellar Lymphoseek sales on Wednesday of $1,000,000 will not be sufficient to turn this around. Last quarter (which was only a partial quarter) we had $195,000 in revenue. $500,000 will satisfy me, but no one knows what the market is expecting. The Oldtimers seem to be expecting less than $500,000. Let us hope this is wrong.

More important than sales, we need a major RIGS development. THE COMPANY SHOULD HAVE SPECIFIED THE DAY AFTER THE CREDE DEAL WENT THROUGH WHAT THE $30 MILLION WAS FOR EXACTLY. BY SAYING NOTHING (AND DELIBERATELY S0) THEY HAVE DIRECTLY CONTRIBUTED TO THE DEPRESSED SHARE PRICE.

The only way I see this stock trending back toward 3.00 or beyond is with the official start of the RIGS Phase III trial. Everything else is minor.

And fwiw, it seems like many Oldtimers have sold large portions of their positions on the way down and that's the ONLY reason they are not as mad as many others.

I am surprised that no law firm has stepped up to file a suit on behalf of shareholders the way some law firms have "investigated" NAVB in previous months over far less pps declines than we are seeing now.

What a hard kick in the face this financing has turned out to be for the Oldtimers and all longs.

I hope the $30 million was worth this unimaginable loss in market cap and share price.

The company damn well better persuade the market with sales numbers and whatever else Wednesday or this stock will be headed even lower.

Considering this unimaginable decline in share price, I have to believe that during the coming CC, management will be asked some very difficult questions about the GE and Crede financing terms and why such was all necessary.

I also believe the tone of voice used in addressing management will be far less than friendly.

Yuri has been very quiet for more than a year regarding NAVB.

Sheff seems to be ignoring NAVB now and rightfully so.

There is no insider buying. Sales are likely to be weak - even if sales are $400,000 which is double the last partial quarter results, this will be nominal. More Pykett BS.

The European Partnership has not been announced, though the company initially promised April 30th, 2013 as the latest date they would announce it. More Pykett BS.

Lymphoseek was approved at the pps was promptly capped at 3.00 by the shorts and has struggled to hold 3.00 the few times it has been at 3.00 since, like this past Summer. More Pykett BS.

Thanks Mark Pykett and Brent Larson! Why did you hire a new IR firm?

They have done nothing for the stock, just like both of you.

Handcuffs are clearly called for.

You see all of the financing in a positive light. Ok. My question is, how long will it take for the share price to return to 2.84?

I want the share price to be much higher than 2.84 of course, but my realistic side is saying that 2.50 will be a monumental achievement when it happens next and holds.

Even yesterday, 1,720,487 shares traded. How long can this extremely high volume last in the 2.00 range?

If the shorts have only covered 1,000,000 shares again when the next short interest report comes out around 11/9, then it seems to me as if the shorts are planning to take NAVB much lower - and will have an opportunity to do so if sales are not at least respectable in this weeks CC.

Thanks mosserman. It might damage Crede's reputation to sell shares immediately after buying them. Companies in the future could avoid Crede if they have a habit of destroying the companies they invest in. At first, it seemed as though Crede is beneficial to the companies they invest in. If they have been loaning the shares to short and management is planning a MAJOR announcement simultaneously that European Approval has been granted and that the company is partnering with X, Y, and Z to expedite sales in Europe, the pps could rebound nicely and short covering could take the pps back to the Crede purchase price easily. If the company announces the new sNDA at the same time, this could also propel the stock back upwards. They sure owe it to shareholders to turn this mess around that they insisted on creating with toxic financing.

I still want to know why RIGS is not on the front burner at this time. The company knows full well that RIGS is the main revenue and profit generator that they have. Lymphoseek is a Lollypop compared to a steak by comparison. The company is not starting RIGS from the ground up - they have cancer survivors who were successfully treated by RIGS in the late 1980s and early 1990s. It is time to wake up the giant!

Does anyone else think that Crede may be in bed with the shorts, at least for now?

What if Crede isn't selling and instead, they have been loaning their shares out to the shorts?
This disgusting mess seems far from over no matter what the company does right as every major PR is shorted into. Great job Pykett!

Indeed. Accountability is long overdue with this whole situation.

In the smallest print of the Crede deal, I hear that it read:

Under no circumstances will the company be sold to another party for any share price above 1.75 per share. If the company is offered 4.40 per share for example, the company shall and must convince the buying entity that the company is worth much, much less. And of paramount importance, all shareholders must be misled by all resulting press releases so that the shorts and hedge funds can control the share price of NAVB indefinitely.

The Streamer must be malfunctioning!

2.00 X 2.01

Do we close at 1.90?

I hope Brent Larson (or whoever the hell speaks at the CC) is prepared to answer tough questions accurately and thoughtfully. Anything less and we could lose another dollar in share price.

And if they refuse to answer questions about the Crede deal and the shady way that the company has been wording things, the pps could go under 1.00. Beautiful.

All I'm saying regarding the phone calls to shorts is that at least one insider at Navidea confirmed for a major short years ago that a major dilutive event would definitely happen in the future.

The event has happened. If the shorts are not covering in the next short interest report (but only shorting more like I think is possible) then this could be the end.

This stock is trading 1,000,000+ shares per day on down volume.

And the fact that Oldtimers do not appear angry at all tells me that they have wisely contributed to the dumping over the past 22 days.

They understood the GE/Crede reality ahead of the rest of us.

A real turnaround could be more than a year away or will never happen as the company has ruined their credibility with hundreds of selling shareholders.

If Crede or some other corrupt financial institution approached the company right now and offered 1.00 per share for 60,000,000 shares, I have no doubt the company would jump on it. They could collect paychecks for 20 more years and do nothing whatsoever else.

I'm surprised there have been any insider buys in the past 12 months. I'm surprised there has been ANY short covering until NOW.
Can this be turned around? It will take much more than sales.

Filing the anticipated sNDA might be a start.

The salaries are an excellent point. By raising the $30 million, the company will last for years to come no matter how low the share price drops. And in those years to come, high salaries will be paid whether the company delivers or not. The financing benefits the employees more than the company itself and cost share holders millions of dollars.

It is also troubling that RIGS is not a Q4 catalyst anymore. What a great way for the company to make sure that the pps stays at or below 2.00. Keep RIGS on the shelf instead of developing it further and enhancing shareholder value. This all adds up to the company harming its shareholders.

It seems as though 1.50 could come next week with the sales report, regardless of what the dollar figure is, the shorts will manage to portray it as less than good.

This is not accidental. I wonder why Brent Larson allowed the shorts to cover a few million shares in the past two months. He should have been telling them to wait until after the Crede deal destroys the company. THEY ALL KNEW DAMN WELL WHAT WAS GOING TO HAPPEN WITH THE CREDE DEAL.

The stock has been in decline for 22 straight trading days. We have never seen or even imagined this before. It is becoming increasingly clear that there is an illegal leak of information from Navidea Corporate Headquarters to the largest shorts. The shorts likely knew years in advance that this toxic financing was coming. Was it Brent Larson that told them in some secret phone call? Was it Pykett himself? The GE line of credit was a rouse to make the company appear much stronger than it really is. At the end of the day, $30 million from Crede was not worth a loss of more than $100 million in market cap. This is a scam and we have all been had.

Regardless of sales, this stock is headed much lower.

I made $49,234 trading the stock since December 2010. I sold my 54,700 shares that I was currently holding between 2.07 and 2.24 for a loss of 23,820. My net gain for NAVB was around $26,000.

3.83 is never going to happen. Heck, 2.83 seems light years away. The company has sacrificed more than $100 million for a measly $30 million. If the GE line of credit deal had the 6X burn rate clause, then the company is exceedingly incompetent in management and finance. This stock is being held down so firmly, it reeks of fraud and criminality. I sold out today. 54,700 shares. Goodbye all.

If Lymphoseek gets European Approval (and a partnership with at least mediocre terms is announced by the end of the year) WHY DIDN'T THE COMPANY WAIT TO DO AN OFFERING? An offering when the pps is at 3.50, 4.00, or even higher with the coming milestones would have made much more sense!

This deal was crooked and hurt all retail shareholders. It has allowed shorts to cover before the big news. I have not sold a single share, but some unfortunate individuals have taken an unnecessary loss because the company did this.

Did they need $30 million RIGHT NOW when the GE line of credit is right there? Please speak up folks.

Gee, with so much uncertainty of YOUR OWN, WHY do you BUY NAVB and WHY DO YOU POST HERE?

Why would this law firm care about the options granted to Pykett?

Nice try today by the Shrekeli/Piper types trying to harm NAVB. The more they work to distort the stock based on nonsense, the better I feel about my investment. Mudslinging isn't very effective in politics forever either - people eventually learn to think for themselves.

The last options were granted at 3.08 and there were many. While 3.08 is not a terribly high share price for NAVB, the company has much to do to get the pps above 3.00 and keep it there.

Strong pipeline catalysts will not be undone by baseless statements or intentionlly distracting questions about the company and the skyward direction it is heading in.